Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years is a paper indexed in PICO Portal from OpenAlex.
How many citations does Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years have?
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years has 296 citations in the OpenAlex counts PICO Portal stores.
When was Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years published?
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years has 2013 year in the PICO Portal index.
What is the open-access status of Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years?
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years has bronze oa status in the PICO Portal index.
What is the DOI of Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years?
The DOI for Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years is on the source record.
What is the PMID of Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years?
The PMID for Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years is on the source record.
What is the OpenAlex record for Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years?
The OpenAlex for Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years is on the source record.